Efficacy of oral administration of lentinula eododes mycelia extract for breast cancer patients undergoing postoperative hormone therapy

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3469-3472

  Suzuki, Nobutaka ^a   Takimoto, Yuko ^a   Suzuki, Riho ^a   Arai, Takanari ^a   Uebaba, Kazuo ^b   Nakai, Masuo ^c   Strong, Jeffry Michael ^a   Tokuda, Harukuni ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

^c Department of Orthopaedic Surgery   (Japan)

Author keywords

Breast cancer; BRM; Hormone therapy; Lentinula edodes; QOL

Indexed keywords

EID: 84882565981     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3469     Document Type: Article

References (21)

1. Chihara G, Maeda Y, Hamuro J, et al (1969). Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature, 222, 687-8.
2. Fukuhara S, Bito S (1998). Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol, 51, 1037-44.
3. Hatam N, Ahmadloo N, Ahmad Kia, et al (2011). Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet, 284, 215-20.
4. Heriot AG (2000). Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer, 82, 1009-12.
5. Itoh A, Isoda K, Kondoh M, et al (2009). Hepatoprotective effect of syringic acid and vanillic acid on concanavalin a-induced liver injury. Biol Pharm Bull, 32, 1215-9.
6. Kornblith AB, Lan L, Archer L, et al (2011). Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol, 29, 1022-8.
7. Liu M, Li J, Kong F, Lin J, Gao Y (1998). Induction of immunomodulating cytokines by a new polysaccharidepeptide complex from culture mycelia of Lentinus edodes. Immunopharmacology, 40, 187-98.
8. McHorney CA, Ware JE Jr, Lu JF et al (1994). The MOS 36- item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care, 32, 40-66.
9. Nagashima Y, Sanpei N, Yamamoto S, et al (2005). Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy). Gan To Kagaku Ryoho, 32, 1550-2.
10. Ochayon L, Zelker R, Kaduri L, et al (2010). Relationship between severity of symptoms and quality of life in patients with breast cancer receiving adjuvant hormonal therapy. Oncol Nurs Forum, 37, 349-58.
11. Ohsumi S, Shimozuma K, Ohashi Y, et al (2012). Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: the national surgical adjuvant study of breast cancer 02. Oncology, 82, 131-8.
12. Okuno K, Uno K (2011). Efficacy of orally administered Lentinula edodes mycelia extract for advanced gastrointestinal cancer patients undergoing cancer chemotherapy: a pilot study. Asian Pac J Cancer Prev, 12, 1671-4.
13. Shibata M, Nezu T, Kanou H, et al (2002). Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol, 34, 416-20.
14. Sisirak V, Faget J, Vey N, et al (2013). Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology, 2, 22338.
15. Sugano N, Hibino Y, Choji Y, et al (1982). Anticarcinogenic actions of water-soluble and alcohol-insoluble fractions from culture medium of Lentinus edodes mycelia. Cancer Lett, 17, 109-14.
16. Sugano N, Choji Y, Hibino Y, et al (1985). Anticarcinogenic action of an alcohol-insoluble fraction (LAP1) from culture medium of Lentinus edodes mycelia. Cancer Lett, 27, 1-6.
17. Tanaka K, Ishikawa S, Matsui Y, et al (2011). Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. Cancer Sci, 102, 516-21.
18. Tanaka K, Ishikawa S, Matsui Y, et al (2012).Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice. Cancer Immunol Immunother, 61, 2143-52.
19. Tanigawa K, Ito Y, Sakai M, et al (2012). Evaluation of quality of life and immune function in cancer patients receiving combined immunotherapy and oral administration of Lentinula edodes mycelia extract. Gan To Kagaku Ryoho, 39, 1779-81.
20. van Nes JG, Fontein DB, Hille ET, et al (2012). Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat, 134, 267-76.
21. Yamaguchi Y, Miyahara E, Hihara J (2011). Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. Am J Chin Med, 39, 451-9.